EP0035204B2
(fr)
*
|
1980-03-05 |
1991-05-22 |
Miles Inc. |
Compositions pasteurisées de protéines thérapeutiquement actives
|
JPS56135418A
(en)
*
|
1980-03-27 |
1981-10-22 |
Green Cross Corp:The |
Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
|
US4305871A
(en)
*
|
1980-09-02 |
1981-12-15 |
Edward Shanbrom |
Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
|
DE3043857A1
(de)
*
|
1980-11-21 |
1982-07-08 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
|
DE3045153A1
(de)
*
|
1980-11-29 |
1982-07-08 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
|
IT1194135B
(it)
*
|
1981-01-05 |
1988-09-14 |
Novo Industri As |
Composizioni di plasmina stabilizzata e metodo per la loro preparazione
|
JPS57140724A
(en)
*
|
1981-02-25 |
1982-08-31 |
Green Cross Corp:The |
Heat-treatment of aqueous solution containing cold insoluble globulin
|
US4495278A
(en)
*
|
1981-04-27 |
1985-01-22 |
Baxter Travenol Laboratories, Inc. |
Process for making novel blood clotting enzyme compositions
|
EP0286198B1
(fr)
*
|
1981-04-27 |
1994-12-14 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Compositions d'enzyme coagulant le sang
|
US4480029A
(en)
*
|
1981-04-27 |
1984-10-30 |
Baxter Travenol Laboratories, Inc. |
Biological indicators and their use
|
DE3119157A1
(de)
*
|
1981-05-14 |
1982-12-09 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von und danach hergestelltes plasminogen
|
EP0081482A1
(fr)
*
|
1981-06-18 |
1983-06-22 |
E. G. Birger Blombäck |
Procede de purification et de concentration du complexe de facteur viii
|
JPS5874617A
(ja)
*
|
1981-10-28 |
1983-05-06 |
Green Cross Corp:The |
人由来血液凝固第7因子含有水溶液の加熱処理方法
|
US4845074A
(en)
*
|
1982-05-13 |
1989-07-04 |
Cedars Sinai Medical Center |
Heat treatment of Factor VIII
|
US4456590B2
(en)
*
|
1981-11-02 |
1989-05-30 |
|
Heat treatment of lyphilized blood clotting factor viii concentrate
|
US4556558A
(en)
*
|
1982-05-13 |
1985-12-03 |
Cedars-Sinai Medical Center |
Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
|
DE3230849A1
(de)
*
|
1982-08-19 |
1984-02-23 |
Behringwerke Ag, 3550 Marburg |
Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
|
DE3237512A1
(de)
*
|
1982-10-09 |
1984-04-12 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
|
US4470968A
(en)
*
|
1983-01-13 |
1984-09-11 |
Miles Laboratories, Inc. |
Pasteurized therapeutically active blood coagulation factor concentrates
|
JPS59134730A
(ja)
*
|
1983-01-20 |
1984-08-02 |
Green Cross Corp:The |
血液凝固第8因子の加熱処理法
|
AT376881B
(de)
*
|
1983-05-02 |
1985-01-10 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
|
ATE36457T1
(de)
*
|
1983-05-02 |
1988-09-15 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
|
DE3481109D1
(de)
*
|
1983-05-09 |
1990-03-01 |
Novo Nordisk As |
Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
|
HUT40311A
(en)
*
|
1983-06-03 |
1986-12-28 |
Kiskunhalasi Aag |
Process for producing protein concentrates, blood-curd and nutriments from blood and its elements
|
DE3330770A1
(de)
*
|
1983-08-26 |
1985-03-14 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur pasteurisierung von humanplasma
|
JPS6054287B2
(ja)
*
|
1983-10-19 |
1985-11-29 |
株式会社ミドリ十字 |
血漿蛋白の加熱処理方法
|
US4490361A
(en)
*
|
1983-12-02 |
1984-12-25 |
Alpha Therapeutic Corporation |
Virus inactivating heat treatment of plasma fractions
|
AT389815B
(de)
*
|
1984-03-09 |
1990-02-12 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
|
US5281579A
(en)
*
|
1984-03-23 |
1994-01-25 |
Baxter International Inc. |
Purified virus-free hemoglobin solutions and method for making same
|
US5043428A
(en)
*
|
1984-08-31 |
1991-08-27 |
Behringwerke Aktiengesellschaft |
Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
|
AT390001B
(de)
*
|
1984-09-28 |
1990-03-12 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
|
DE3602688A1
(de)
*
|
1986-01-30 |
1987-08-06 |
Behringwerke Ag |
Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
|
DE3621371A1
(de)
*
|
1986-03-12 |
1987-09-17 |
Behringwerke Ag |
Gentechnische herstellung von faktor xiiia
|
JPH0725696B2
(ja)
*
|
1986-05-29 |
1995-03-22 |
株式会社ミドリ十字 |
プラスミノ−ゲンの安定化方法
|
DE3622642A1
(de)
*
|
1986-07-05 |
1988-01-14 |
Behringwerke Ag |
Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
|
CA1310267C
(fr)
*
|
1986-07-09 |
1992-11-17 |
Yutaka Hirao |
Procede pour le thermotraitement de _-globuline non modifiee
|
US4749783A
(en)
*
|
1986-07-11 |
1988-06-07 |
Miles Laboratories, Inc. |
Viral inactivation and purification of active proteins
|
DE3625090A1
(de)
*
|
1986-07-24 |
1988-01-28 |
Behringwerke Ag |
Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
|
AT391808B
(de)
*
|
1986-11-03 |
1990-12-10 |
Immuno Ag |
Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
|
JPS63243032A
(ja)
*
|
1987-03-27 |
1988-10-07 |
Green Cross Corp:The |
トロンビンの加熱処理方法
|
US4876241A
(en)
*
|
1987-05-22 |
1989-10-24 |
Armour Pharmaceutical Company |
Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
|
AU2423988A
(en)
*
|
1987-08-17 |
1989-03-09 |
Liposome Company, Inc., The |
A sponge enzyme having transglutaminase-like activity
|
DK18288D0
(da)
*
|
1988-01-15 |
1988-01-15 |
Nordisk Gentofte |
Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
|
US5981485A
(en)
*
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
US5763394A
(en)
*
|
1988-04-15 |
1998-06-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
US5096885A
(en)
*
|
1988-04-15 |
1992-03-17 |
Genentech, Inc. |
Human growth hormone formulation
|
AU2684488A
(en)
|
1988-06-27 |
1990-01-04 |
Carter-Wallace, Inc. |
Test device and method for colored particle immunoassay
|
JPH0341033A
(ja)
*
|
1989-07-07 |
1991-02-21 |
Kyowa Hakko Kogyo Co Ltd |
安定なモチリン類含有製剤
|
FR2650508A1
(fr)
*
|
1989-08-01 |
1991-02-08 |
Fondation Nale Transfusion San |
Colle pasteurisee pour reunir des tissus humain ou animal
|
DE3926034C3
(de)
*
|
1989-08-07 |
1996-11-21 |
Behringwerke Ag |
Verfahren zur Herstellung eines stabilen Faktors VIII
|
DE4001451A1
(de)
*
|
1990-01-19 |
1991-08-01 |
Octapharma Ag |
Stabile injizierbare loesungen von faktor viii und faktor ix
|
JPH03240738A
(ja)
*
|
1990-02-20 |
1991-10-28 |
Hoechst Japan Ltd |
糖尿病性壊疽治療剤
|
JPH0813750B2
(ja)
*
|
1990-03-01 |
1996-02-14 |
持田製薬株式会社 |
経口用トロンビン製剤
|
FR2664165B1
(fr)
|
1990-07-03 |
1992-10-16 |
Lille Transfusion Sanguine |
Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
|
US5314695A
(en)
†
|
1990-11-13 |
1994-05-24 |
Corvas International, Inc. |
Tissue factor based prothrombin time reagent
|
AT402891B
(de)
*
|
1991-06-20 |
1997-09-25 |
Immuno Ag |
Verfahren zur herstellung eines inaktivierten blutproduktes
|
US5792835A
(en)
*
|
1991-09-05 |
1998-08-11 |
Baxter International Inc. |
Method of preparing a topical fibrinogen complex
|
AT399818B
(de)
*
|
1992-04-24 |
1995-07-25 |
Immuno Ag |
Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
|
JP3133338B2
(ja)
*
|
1992-12-16 |
2001-02-05 |
イムノ・アクチエンゲゼルシャフト |
ウイルス的に安全な生物学的組成物の調製方法
|
DE69426292T2
(de)
*
|
1993-02-23 |
2001-05-17 |
Genentech, Inc. |
Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
|
US5330974A
(en)
*
|
1993-03-01 |
1994-07-19 |
Fibratek, Inc. |
Therapeutic fibrinogen compositions
|
WO1994022471A1
(fr)
*
|
1993-04-05 |
1994-10-13 |
The Green Cross Corporation |
Preparation liquide d'antithrombine iii et procede pour sa stabilisation
|
DE4320294A1
(de)
*
|
1993-06-18 |
1994-12-22 |
Immuno Ag |
Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
|
DE4325872C1
(de)
*
|
1993-08-02 |
1994-08-04 |
Immuno Ag |
Virusinaktivierte Faktor Xa-Präparation
|
AT402788B
(de)
*
|
1993-08-03 |
1997-08-25 |
Immuno Ag |
Virussichere blutgerinnungsfaktor xiii-präparation
|
CA2195127C
(fr)
*
|
1994-07-14 |
2007-06-19 |
Ruth Laub |
Concentre de fibrinogene issu de plasma sanguin, procede et installation pour sa preparation
|
US5580856A
(en)
*
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
US6030821A
(en)
*
|
1994-10-11 |
2000-02-29 |
Ajinomoto Co., Inc. |
Stabilized transglutaminase and enzyme preparation containing the same
|
DE19508192A1
(de)
*
|
1995-03-09 |
1996-09-12 |
Behringwerke Ag |
Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
|
SE9501189D0
(sv)
*
|
1995-03-31 |
1995-03-31 |
Pharmacia Ab |
Protein formulation
|
JPH08333277A
(ja)
*
|
1995-06-05 |
1996-12-17 |
Hoechst Japan Ltd |
ヒト血液凝固第xiii因子の安定化された水性液製剤
|
DE96923791T1
(de)
|
1995-07-14 |
2004-07-08 |
Croix Rouge De Belgique |
Verfahren und vorrichtung zur inaktivierung von verunreinigungen in blutprodukten
|
US5733884A
(en)
|
1995-11-07 |
1998-03-31 |
Nestec Ltd. |
Enteral formulation designed for optimized wound healing
|
DE69733664T3
(de)
|
1996-04-19 |
2011-04-14 |
Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles |
Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
|
EP0844254A3
(fr)
*
|
1996-11-20 |
1999-05-12 |
The Green Cross Corporation |
Procédé de production de l'antithrombine-III, son procédé de purification, et préparation la contenant
|
GB9711927D0
(en)
*
|
1997-06-09 |
1997-08-06 |
Bristol Myers Squibb Co |
Compositions useful as fibrin sealants
|
AUPO871997A0
(en)
*
|
1997-08-25 |
1997-09-18 |
Csl Limited |
Dried biologically or therapeutically active preparations
|
AT407484B
(de)
*
|
1997-11-12 |
2001-03-26 |
Bio Prod & Bio Eng Ag |
Arzneimittel zur förderung der wundheilung
|
WO1999055310A1
(fr)
|
1998-04-27 |
1999-11-04 |
Altus Biologics Inc. |
Cristaux de proteines stabilisees, formulations renfermant lesdits cristaux et leurs procedes de fabrication
|
ES2404074T3
(es)
|
1998-08-06 |
2013-05-23 |
Mountain View Pharmaceuticals, Inc. |
Conjugados de peg-oxidasa de urato y su uso
|
DE19856443A1
(de)
|
1998-12-08 |
2000-06-21 |
Centeon Pharma Gmbh |
Stabilisiertes Antithrombin III-Präparat
|
RU2244556C2
(ru)
|
1999-02-22 |
2005-01-20 |
Юниверсити Оф Коннектикут |
Новые не содержащие альбумин составы фактора viii
|
US6733985B1
(en)
*
|
1999-05-19 |
2004-05-11 |
International Technidyne Corporation |
Preparation of stable liquid and dried synthetic prothrombin time reagents
|
US6586574B1
(en)
*
|
1999-08-17 |
2003-07-01 |
Nn A/S |
Stabilization of freeze-dried cake
|
US6890896B1
(en)
|
1999-11-18 |
2005-05-10 |
Ceremedix, Inc. |
Compositions and methods for counteracting effects of reactive oxygen species and free radicals
|
EP2368898B1
(fr)
|
1999-11-18 |
2014-10-01 |
Ischemix, Inc |
Compositions et procédés pour contrecarrer les effets des espèces d'oxygène réactives et des radicaux libres
|
DK1254159T3
(da)
|
2000-01-28 |
2006-09-11 |
Sanofi Aventis Deutschland |
Fremgangsmåde til fremstilling af acetylamidiniophenylalanylcyclohexylglycylpyridylalaninamider
|
DE10012732A1
(de)
*
|
2000-03-18 |
2001-09-20 |
Aventis Behring Gmbh |
Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
|
US6992065B2
(en)
|
2000-04-19 |
2006-01-31 |
Genentech, Inc. |
Sustained release formulations
|
DE10022092A1
(de)
|
2000-05-08 |
2001-11-15 |
Aventis Behring Gmbh |
Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
|
US20020176796A1
(en)
*
|
2000-06-20 |
2002-11-28 |
Purepulse Technologies, Inc. |
Inactivation of microbes in biological fluids
|
JP2002112765A
(ja)
*
|
2000-08-01 |
2002-04-16 |
Nihon Pharmaceutical Co Ltd |
ウイルス不活化法
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
CA2439120C
(fr)
*
|
2001-02-23 |
2011-07-05 |
Genentech, Inc. |
Polymeres erodables a injecter
|
EP1401862A4
(fr)
*
|
2001-05-17 |
2004-12-15 |
Ceremedix Inc |
Composes de peptides contrecarrant lessubstances oxygenees et les radicaux libres
|
ES2554106T3
(es)
*
|
2001-06-21 |
2015-12-16 |
Genentech, Inc. |
Formulación de liberación sostenida
|
AR034749A1
(es)
*
|
2001-07-09 |
2004-03-17 |
Schering Ag |
Formulaciones de interferon beta humano
|
CA2470511C
(fr)
|
2001-12-21 |
2014-05-27 |
Novo Nordisk Health Care Ag |
Composition liquide de polypeptides de facteur vii
|
CN1606452A
(zh)
*
|
2001-12-21 |
2005-04-13 |
诺沃娜第克公司 |
修饰的因子ⅶ多肽的液体组合物
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
ES2523655T5
(es)
|
2002-06-21 |
2018-04-23 |
Novo Nordisk Health Care Ag |
Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
|
AT501088A2
(de)
*
|
2002-12-18 |
2006-06-15 |
Bio Prod & Bio Eng Ag |
Stabile therapeutische proteine
|
KR20050110682A
(ko)
*
|
2003-03-18 |
2005-11-23 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 vii 폴리펩티드의 액상 수성 약학적 조성물
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
US20040229778A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Elmaleh David R. |
Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
|
US7498130B2
(en)
*
|
2003-05-13 |
2009-03-03 |
Massachusetts General Hospital |
Method of reducing viral load
|
WO2004103398A1
(fr)
*
|
2003-05-23 |
2004-12-02 |
Novo Nordisk Health Care Ag |
Stabilisation de proteines dans une solution
|
JP4658041B2
(ja)
*
|
2003-06-25 |
2011-03-23 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドの液体組成物
|
WO2005002615A1
(fr)
*
|
2003-07-01 |
2005-01-13 |
Novo Nordisk Health Care Ag |
Preparations pharmaceutiques aqueuses liquides de polypeptides facteur vii
|
MXPA06001698A
(es)
|
2003-08-14 |
2006-05-19 |
Novo Nordisk Healthcare Ag |
Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
|
EP3378470A1
(fr)
*
|
2003-12-19 |
2018-09-26 |
Novo Nordisk Health Care AG |
Compositions stabilisées de polypeptides de facteur vii
|
KR100624013B1
(ko)
*
|
2004-06-25 |
2006-09-19 |
주식회사 녹십자홀딩스 |
동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
US8148123B2
(en)
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
MX2007012548A
(es)
*
|
2005-04-11 |
2008-03-11 |
Savient Pharmaceuticals Inc |
Formas variantes de urato oxidasa y uso de las mismas.
|
EP1883425A1
(fr)
*
|
2005-05-23 |
2008-02-06 |
Universite De Geneve |
Nanoparticules superparamagnetiques injectables destinees a un traitement par hyperthermie et a la formation d'un implant
|
WO2007005482A1
(fr)
*
|
2005-06-30 |
2007-01-11 |
Ge Healthcare Bio-Sciences Corp. |
Procede de detection d'expression genique
|
HU230758B1
(hu)
*
|
2006-04-12 |
2018-03-28 |
Crealta Pharmaceuticals LLC 100% |
Fehérjék tisztítása kationos felületaktív anyaggal
|
EP2268267B1
(fr)
*
|
2008-04-21 |
2017-06-14 |
Novo Nordisk Health Care AG |
Composition de transglutaminase sèche
|
ES2548378T3
(es)
|
2008-11-04 |
2015-10-16 |
Aska Pharmaceutical Co., Ltd. |
Composición acuosa que contiene hormona foliculoestimulante
|
JP5779780B2
(ja)
|
2008-11-07 |
2015-09-16 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
第viii因子製剤
|
EP3482768A1
(fr)
|
2009-06-25 |
2019-05-15 |
Horizon Pharma Rheumatology LLC |
Procédés et kits pour prédire le risque de réaction de perfusion et perte induite par anticorps de la réponse par surveillance de l'acide urique sérique pendant une thérapie uricase pégylée
|
NZ601927A
(en)
|
2010-04-27 |
2013-07-26 |
Scil Technology Gmbh |
Stable aqueous mia/cd-rap formulations (cartilage derived retinoic acid sensitive protein)
|
IL213864A0
(en)
|
2011-06-30 |
2011-08-31 |
Omrix Biopharmaceuticals Ltd |
Method for removing a lytic enzyme from a heterogeneous mixture
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
EP3039039B1
(fr)
|
2013-08-30 |
2021-03-10 |
Takeda GmbH |
Anticorps neutralisant le gm-csf destiné à être utilisé dans le traitement de la polyarthrite rhumatoïde ou comme analgésique
|
RU2556804C2
(ru)
*
|
2013-12-17 |
2015-07-20 |
Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ |
Способ получения концентрата фибриногена
|
IL231230A0
(en)
|
2014-02-27 |
2014-08-31 |
Omrix Biopharmaceuticals Ltd |
Fibrinogen preparation
|
CA2946230A1
(fr)
|
2014-05-07 |
2015-11-12 |
Takeda Gmbh |
Formulation liquide comprenant un compose neutralisant gm-csf
|
TWI705822B
(zh)
|
2014-12-19 |
2020-10-01 |
美商波麥堤克生物治療股份有限公司 |
包含纖維蛋白溶酶原之醫藥組合物及其用途
|
IL247821A0
(en)
|
2016-09-14 |
2017-01-31 |
Omrix Biopharmaceuticals Ltd |
Adhesive preparations and their use
|
JP7501357B2
(ja)
*
|
2018-03-23 |
2024-06-18 |
味の素株式会社 |
トランスグルタミナーゼを含有する液体製剤
|
WO2019201894A1
(fr)
*
|
2018-04-16 |
2019-10-24 |
Merck Patent Gmbh |
Additifs pour formulations protéiques en vue d'améliorer la stabilité thermique
|
WO2020121289A1
(fr)
|
2018-12-12 |
2020-06-18 |
Omrix Biopharmaceuticals Ltd. |
Compositions de protéines faiblement concentrées destinées à prévenir l'adhérence tissulaire
|
IL263679A
(en)
|
2018-12-12 |
2019-03-31 |
Omrix Biopharmaceuticals Ltd |
Kits, methods, and ingredients for preventing tissue adhesion
|
WO2023119277A1
(fr)
|
2021-12-21 |
2023-06-29 |
Omrix Biopharmaceuticals Ltd. |
Compositions de fibrinogène hautement solubles
|